Results 31 to 40 of about 388 (104)

Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria

British Journal of Dermatology, 2015
In erythropoietic protoporphyria (EPP), an inherited disease of porphyrin-biosynthesis, the accumulation of protoporphyrin in the skin causes severely painful phototoxic reactions. Symptom prevention was impossible until recently when afamelanotide became available.
G, Biolcati, E, Marchesini, F, Sorge, L, Barbieri, X, Schneider-Yin, E I, Minder   +5 more
openaire   +2 more sources

The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study

British Journal of Dermatology
Abstract Background Patients with erythropoietic protoporphyria experience lifelong painful photosensitivity resulting in a lack of sunlight exposure. Previous studies have shown that 47–63% of patients with EPP suffer from vitamin D deficiency and a high prevalence of osteoporosis.
Kluijver, Louisa G., Nekouei Shahraki, Mitra, Wagenmakers, Margreet A.E.M., Hanssen, Bettina E., Kuerten, Viola, Schelonke, Kathrin, Homey, Bernhard, Langendonk, Janneke G.   +7 more
openaire   +2 more sources

Afamelanotide [PDF]

, 2020
openaire   +1 more source

Current trials in erythropoietic protoporphyria: are placebo controls ethical? [PDF]

Orphanet J Rare Dis, 2023
Barman-Aksözen J, Andreoletti M, Blasimme A.   +2 more
europepmc   +1 more source

Illuminating Dersimelagon: A Novel Agent in the Treatment of Erythropoietic Protoporphyria and X-Linked Protoporphyria. [PDF]

Pharmaceuticals (Basel), 2023
Madigan KE, Rudnick SR, Agnew MA, Urooj N, Bonkovsky HL.   +4 more
europepmc   +1 more source

THE COST EFFECTIVENESS OF AFAMELANOTIDE FOR THE TREATMENT OF ERYTHROPOIETIC PROTOPORHYRIA [PDF]

Value in Health, 2016
J.C. Thompson, S. Mealing, D. Vetrini, P. Wolgen   +3 more
openaire   +1 more source

Burden of illness and unmet needs in patients with erythropoietic protoporphyria and X-linked protoporphyria: A large US nationwide claims analysis. [PDF]

J Manag Care Spec Pharm
DerSarkissian M, Norregaard C, Romdhani H, Muthukumar A, Bobbili P, Chin M, Liu W, Trinh L.   +7 more
europepmc   +1 more source

Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other Rare Diseases: A Patient-Initiated EQ-5D Feasibility Study. [PDF]

Int J Environ Res Public Health, 2023
Barman-Aksözen J, Minder AE, Granata F, Pettersson M, Dechant C, Aksözen MH, Falchetto R.   +6 more
europepmc   +1 more source

Silica-Assisted Solid-Phase Peptide Synthesis (SiPPS). [PDF]

J Pept Sci
Nkwanyana N, Kumar A, Chakraborty A, Potvin S, Thibaut-Koumba G, Nardone B, Beland F, Sharma A, de la Torre BG, Albericio F.   +9 more
europepmc   +1 more source

Multifactorial Perspective for Greening Solid-Phase Peptide Synthesis: Rigid Polyacrylate Macroporous Resin in Combination with Green Solvents. [PDF]

ChemSusChem
Noki S, Kumar A, Zhang C, Basso A, Serban S, Kou X, Li Y, Sharma A, de la Torre BG, Albericio F.   +9 more
europepmc   +1 more source